Charles (Chuck) Baum

Dr. Baum is the Founder, President and Chief Executive Officer of Mirati Therapeutics and has been a Board member since November 2012. Prior to joining Mirati, Dr. Baum was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. He was at Pfizer from 2003 to 2012, serving in roles of increasing responsibility, including Vice President, Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of Pfizer’s oncology portfolio, including Inlyta, Xalkori and the approval of Sutent. Prior to Pfizer, Dr. Baum was at Schering-Plough where he was responsible for the Phase I-IV development of several oncology compounds, including Temodar. His career has also included academic and hospital positions at Stanford and Emory universities. Dr. Baum serves on the Board of Directors at Poseida Therapeutics, PMV Pharma, Odyssey Therapeutics, and Terremoto Biosciences. He is also on the scientific advisory board at ALX Oncology. Dr. Baum received his M.D. and Ph.D. degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University. Additionally, he has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.

David Berman

Dr. Berman is a Professor and Chair of the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario. He is board certified in Anatomic Pathology and practices urologic surgical pathology at Kingston Health Sciences Centre while also running a biomarker discovery laboratory focused on urologic cancers. Dr. Berman earned his M.D. and Ph.D. (Genetics and Development) degrees from the University of Texas, Southwestern Medical Center. He completed residency training and a postdoctoral research fellowship at Johns Hopkins where he established his independent research laboratory, which moved to Canada in 2012.

The Berman Laboratory focuses on basic, translational, and clinical aspects of prostate and bladder cancer. His research has helped identify bladder cancer stem cells and druggable targets in embryonic signaling pathways, and it has helped improve surgical pathology practice.

Dr. Berman was Director of the Queen’s Cancer Research Institute from 2015-2021 and has served on research advisory committees for the Canadian Cancer Society (ACOR), the Canadian Cancer Trials Group, and Bladder Cancer Canada. He currently leads a translational research effort for the Canadian Bladder Cancer Research Network.

Peter Blume-Jensen

Peter Blume-Jensen, M.D., Ph.D., is Founder, President, and CEO of Acrivon Therapeutics, Inc. He has extensive experience in oncology R&D and oncogenic kinase signaling. From 2001 to 2008, Peter was Department Head at Serono, US and later at Merck & Co, Inc. where he established and led integrated oncology drug programs into the clinic. From 2008 to 2010, he was Vice President, Ext. Sci. Affairs and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo, Inc. He co-led the scientific due diligence and M&A resulting in the acquisition of Plexxikon. From 2010-2014 he was CSO for Metamark Genetics where he built R&D and a novel, scripted proteomics tissue imaging platform. Here he led 4 clinical studies culminating with the blinded validation and launch of ProMark®, an outcome-predictive prostate cancer biopsy test included under NCCN guidelines and coverage. From 2014 till 2018 Peter was CSO for XTuit Pharmaceuticals where he established a novel prodrug platform in collaboration with Dr. Jeremiah Johnson, MIT, now continued at Window Therapeutics. Peter is the inventor of the AP3 platform and the OncoSignature patient selection method.

Peter serves on the SAB for several private biotech companies and academic institutions. His review “Oncogenic Kinase Signaling (Nature, 2001) is a citation classic in the field of clinical medicine. He received his M.D. from Copenhagen University Medical School, Denmark, his Ph.D. from The Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral Fellowship under Tony Hunter at the Salk Institute, La Jolla, CA.

Erick Gamelin

Erick Gamelin, M.D., Ph.D., is Chief Development Officer at Acrivon Therapeutics, Inc. From 2019 to 2021, he served as Chief Medical Officer at Step Pharma, a biotech focused on developing drugs in hematological malignancies. Previously he served as Vice President, Oncology at Dynavax Technologies focused on oncology vaccines and immune therapies, and prior to that as Vice President at Macrogenics Inc., working with immune therapies and bispecifics. Before that, he held leadership positions in early development at the Oncology Vaccine department at Pfizer, and with Targeted Therapies at Amgen.

Erick is a Medical Oncologist and Pharmacologist, former Professor of Oncology, and CEO of a national university cancer center and hospital, the West Oncology Institute. He received the title of Chevalier in the National Order of Merit by the French Minister of Health. During his career in academia, he has led a research lab in oncogenomics and genetics, funded by the French NCI, focused on the mechanisms of acquired resistance of cancer cells. He received his Ph.D. in molecular pharmacology from Bordeaux University and did his Post-Doc at the NIH, Molecular Therapeutics Section, Medical Oncology Branch. He has led over 100 Phase 1-3 oncology trials and coauthored more than 135 articles in peer-reviewed international journals.